News & Updates

Patients with gout consider flare duration, flare frequency, and pain severity when thinking about treatment efficacy over time, according to a study. Of these factors, shorter flare duration is deemed to be the most common indicator of successful treatment.

Use of opioid among adults with knee and/or hip osteoarthritis (OA) often leads to being familiar with the treatment and believing that the medication is beneficial and low-risk, reveals a recent study.

Patients with psoriatic arthritis exhibit reduced hand grip strength, with the deterioration of skill, coordination, and functionality of hand commensurate with the severity of psoriatic arthritis, a study has found.

Treatment with the monoclonal antibody targeting interleukin [IL]-23p19 guselkumab 100 mg, given either every 4 (Q4W) or 8 weeks (Q8W), is well tolerated in patients with psoriatic arthritis (PsA), with no new safety concerns through 1 year, according to pooled results of the DISCOVER-1 and DISCOVER-2 phase III trials.

The monoclonal antibody ixekizumab improved the signs and symptoms of psoriatic arthritis (PsA) in PsA patients with inadequate response to one or two tumour necrosis factor inhibitors (TNFis), suggests results from a post hoc subanalysis of the SPIRIT-P2 trial.

Circulating homocysteine and C677T variant in methylenetetrahydrofolate reductase (MTHFR) appear to influence the prevalence rate and ensuing progression of spinal osteoarthritis (OA), respectively, in postmenopausal women, a study has shown.

The interleukin (IL)-23p19-subunit inhibitor guselkumab appears to produce improvements in multiple disease domains of psoriatic arthritis (PsA) with no unexpected safety findings through 2 years of treatment in biologic-naïve patients, according to the phase III DISCOVER-2 trial.